Preliminary results from eight patients in the phase I portion of the Acclaim-1 clinical study evaluating Reqorsa immunogene therapy (quaratusugene ozeplasmid) with Tagrisso (osimertinib) in patients with advanced, EGFR mutant non-small cell lung cancer whose disease progressed after Tagrisso showed that Reqorsa was generally well tolerated, as there were no dose limiting toxicities. Promising efficacy results were also observed.
The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.
